Chandra Bhagat Pharma Share Price Today | Stock Price & Chandra Bhagat Pharma Share Screener
Track the current Chandra Bhagat Pharma share price and stock price live with TickJournal's free stock screener. Track CBPL market value to gauge the company's total market size. Use the Chandra Bhagat Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Chandra Bhagat Pharma opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Chandra Bhagat Pharma Share Price Chart
Track the current stock price of Chandra Bhagat Pharma with an interactive chart. Analyse CBPL share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Chandra Bhagat Pharma stock quote in one place.
Chandra Bhagat Pharma Company Profile - Fundamental Screener
Screen Chandra Bhagat Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for CBPL shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE07QQ01016.
Company Details
Classification
Identifiers and Leadership
Chandra Bhagat Pharma Balance Sheet Screener
Screen CBPL balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹94, down from ₹102 in 2025.
Latest statistics put total assets at ₹94 and shareholder funds at ₹33, with a leverage ratio of 0.59.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
Assets |
||||||||
| Total Assets | 94 | 102 | 102 | 61 | 73 | 72 | 75 | 83 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 3 | 3 | 3 | 1 | 1 | 0 | 0 | 1 |
Liabilities |
||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 3 | 2 | 2 | 6 | 8 | 13 | 15 | 16 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||
| Total Equity | 33 | 30 | 29 | 28 | 27 | 26 | 26 | 14 |
| Share Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 1 |
| Reserves & Surplus | 26 | 22 | 22 | 20 | 19 | 18 | 18 | 14 |
Chandra Bhagat Pharma Income Statement Screener - Profit & Revenue Analysis
Screen Chandra Bhagat Pharma income statement and profit fundamentals. Analyze CBPL quarterly results. Chandra Bhagat Pharma reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹0 and net profit was ₹0.
In that period expenses were ₹0, interest cost ₹0 and tax ₹0. The next period listed, 2026-March, shows revenue of ₹120 and net profit of ₹3.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March |
|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||
| Revenue | 0 | 120 | 92 | 233 | 120 | 96 | 71 | 94 | 107 |
| Expenses | 0 | 112 | 88 | 228 | 116 | 91 | 67 | 91 | 102 |
Operating Costs and Margins | |||||||||
| EBITDA | 0 | 7 | 4 | 4 | 4 | 4 | 4 | 4 | 5 |
| Operating Profit % | 0.00% | 3.00% | 1.00% | -3.00% | 3.00% | 3.00% | 5.00% | 3.00% | 4.00% |
| Depreciation | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 2 | 2 | 1 | 2 | 3 | 4 | 3 | 4 |
Profit and Earnings | |||||||||
| Profit Before Tax | 0 | 4 | 1 | 2 | 1 | 1 | 0 | 0 | 1 |
| Tax | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 3 | 1 | 2 | 1 | 1 | 0 | 0 | 1 |
| EPS | 0.00 | 4.04 | 1.14 | 2.03 | 1.20 | 1.06 | 0.25 | 0.55 | 13.38 |
Chandra Bhagat Pharma Cash Flow Screener - Liquidity Fundamentals
Screen CBPL cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹9, and net cash flow was an inflow of ₹3.
Over the same period, investing activities provided ₹0 and financing activities used ₹6.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 9 | -6 | 6 | 5 | 12 | 8 | -7 | 4 | -6 | -9 |
| Investing Activities | 0 | -1 | -2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Financing and Net Cash | ||||||||||
| Financing Activities | -6 | 2 | -6 | -4 | -10 | -6 | 7 | -4 | 7 | 8 |
| Net Cash Flow | 3 | -4 | -2 | 1 | 3 | 2 | 0 | 0 | 0 | -1 |
Chandra Bhagat Pharma Shareholding Pattern Screener
See Chandra Bhagat Pharma shareholding pattern with promoter, FII, and DII holdings. Check Chandra Bhagat Pharma promoter holding and ownership changes for CBPL on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Sept, promoters held 73.02%, foreign institutions 0.00%, domestic institutions 0.00% and the public 12.58%, spread across 290 shareholders.
The shareholder count was 290 in 2026-Sept, compared with 280 in 2026-Mar.
| Item | 2026-Sept | 2026-Mar | 2025-Sept | 2025-Mar | 2024-Sept | 2024-Mar | 2023-Sept | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 73.02% | 73.02% | 72.19% | 71.20% | 69.29% | 68.77% | 68.69% | 68.24% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.61% | 0.61% | 0.48% | 1.33% | 1.33% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.89% | 0.89% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 12.58% | 11.33% | 11.84% | 11.16% | 12.84% | 16.92% | 17.07% | 18.98% |
| Other Holding | 14.41% | 15.65% | 15.36% | 17.03% | 17.39% | 12.09% | 12.02% | 12.78% |
| Shareholder Count | 290 | 280 | 301 | 316 | 315 | 152 | 134 | 146 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Chandra Bhagat Pharma. Chandra Bhagat Pharma dividend yield can be compared with peers and other stocks in the market.
Chandra Bhagat Pharma Stock Index Membership - Nifty & Sensex
See which indices include Chandra Bhagat Pharma stock. Check CBPL index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Chandra Bhagat Pharma Market Events Screener - Corporate Actions
Get Chandra Bhagat Pharma corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Chandra Bhagat Pharma stock events that may affect CBPL share price, along with derivatives, futures and options activity and sector gainers.
8 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 13, 2026, with a record date of November 13, 2026.
It is followed by Annual General Meeting dated September 1, 2026 and Quarterly Result Announcement dated May 25, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-11-13 | 2026-11-13 | Quarterly Result Announcement | NA | 4.23% |
| 2026-09-01 | 2026-09-01 | Annual General Meeting | NA | 28.05% |
| 2026-05-25 | 2026-05-25 | Quarterly Result Announcement | NA | 15.15% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | 0.00% |
| 2025-09-30 | 2025-09-30 | Annual General Meeting | NA | -2.27% |
| 2025-05-29 | 2025-05-29 | Quarterly Result Announcement | NA | 2.11% |
| 2024-11-13 | 2024-11-13 | Quarterly Result Announcement | NA | 2.13% |
| 2024-09-30 | 2024-09-30 | Annual General Meeting | NA | -1.31% |
Chandra Bhagat Pharma Competitors Screener - Peer Stocks Comparison
Screen CBPL competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 448,676 | 40.80 | 61,674 | 12.69% | 11,565 | 60.46 |
| Divis Laboratories | 295,997 | 87.70 | 11,067 | 13.95% | 2,568 | 68.76 |
| Torrent Pharmaceuticals | 177,586 | 85.00 | 13,886 | 20.34% | 2,138 | 47.23 |
| Laurus Labs | 126,325 | 89.90 | 6,868 | 22.01% | 890 | 57.04 |
| Zydus Life Science | 120,119 | 27.60 | 27,658 | 17.64% | 5,026 | 55.91 |
| Dr Reddys Laboratories | 115,854 | 41.80 | 35,059 | 3.90% | 4,158 | 71.26 |
| Cipla | 112,131 | 39.50 | 29,045 | 2.24% | 3,870 | 53.06 |
| Mankind Pharma | 107,805 | 47.90 | 14,636 | 14.85% | 1,938 | 61.37 |
| Aurobindo Pharma | 103,229 | 25.80 | 34,145 | 5.56% | 3,503 | 60.39 |
| Lupin | 89,172 | 17.30 | 29,039 | 26.75% | 5,356 | 39.39 |
Chandra Bhagat Pharma Company Announcements - News & Reports Screener
Screen CBPL latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated November 16, 2026.
The next most recent announcements are dated November 16, 2026 and November 10, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-11-16 | Financial Result As On 30Th September 2026. | - |
| 2026-11-16 | Board Meeting Outcome for Outcome Of Board Meeting Held On 13Th November 2026 | - |
| 2026-11-10 | Board Meeting Intimation for Approval Of Un-Audited Results As On 30Th September 2026. | - |
| 2026-10-27 | Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 | - |
| 2026-10-27 | Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 | - |
| 2026-10-26 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-10-22 | Announcement under Regulation 30 (LODR)-Allotment | - |
| 2026-10-21 | Certificate For Non-Applicability Of Corporate Governance For The Quarter Ended 30Th September 2026. | - |
| 2026-10-13 | Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015 For Receipt Of BSE IP Approval | - |
| 2026-10-01 | Closure of Trading Window | - |
| 2026-09-30 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-09-03 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-09-01 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-08-20 | Corrigendum Of AGM Notice | - |
| 2026-08-06 | Notice Of Shareholders Meeting Scheduled On 1St September 2026 | - |
| 2026-08-06 | Reg. 34 (1) Annual Report. | - |
| 2026-08-05 | Board Meeting Outcome for For Approval Of Preferential Issue And Other Agenda | - |
| 2026-07-30 | Board Meeting Intimation for Fund Raising Through Preferential Issue. | - |
| 2026-07-21 | Non-Applicability Of CG Report | - |
| 2026-05-25 | Financial Result For Period Ended 31St March 2026 | - |
Frequently Asked Questions
How is the company valued right now?
The P/B ratio is 1.43. Market capitalisation stands at ₹49.87 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.
About This Data
Key statistics were last updated on November 20, 2026. This page covers 8 balance sheet periods, 9 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.